Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The Chemical Diversity Research Institute (CDRI) has signed collaboration and license option agreement with Novartis Institute for Tropical Diseases (NITD) in Singapore to develop patentable chemical compounds for Tuberculosis treatment (TB).
Subscribe to our email newsletter
NITD received a library of compounds that will be screened in a cell-based assay to identify molecules that are active against the TB causing mycobacterium from CDRI.
As per the deal, CDRI can market such drugs through its affiliate Silvius Pharma in Russia and other countries in the region, whereas Novartis has the right to market them in Asia, Sub-Saharan Africa and other countries.
CDRI chairman of the board Nikolay Savchuk said the company is happy to participate in Public Private Partnership, endorsed by the governments of Singapore and Russia to fight against Tuberculosis.
"Our chemical expertise combined with Novartis commitment to discovering and developing medicines for diseases of the developing world creates unique synergy that will help patients around the globe," Savchuk added.